Thetis Adds Todd Zion and Dennis Willson as Board Advisors

SOUTHPORT, Connecticut, January 3, 2012 — Thetis Pharmaceuticals LLC (“Thetis”), a development stage pharmaceutical company focused on cardio-metabolic disease, announced today the addition of Todd C. Zion, PhD, to its Scientific Advisory Board, and Dennis F. Willson to its Board of Managers. Todd Zion was founder, President and CEO of SmartCells, Inc., a biotechnology company formed in 2003 to develop SmartInsulin™, the first glucose-regulated, injectable formulation for treating diabetes. In December 2010, Merck and Co. acquired SmartCells for over $500M in cash and clinical milestone payments. Dennis F. Willson was formerly the President and CEO of Cytokine PharmaSciences, Inc., a biopharmaceutical company that engages in developing and manufacturing products in the areas of women’s health, inflammation and cancer. A co-founder of Cytokine, Mr. Willson spent 19 years in various leadership roles managing the successful development and licensing of several products, including Cervidil, one of the world’s leading obstetric products. In October 2011, Mr. Willson led the company in a strategic sale to Ferring B.V., a privately held European company with a strong focus on women’s health products. Before joining Cytokine, Mr. Willson held management, finance and business development positions at Abbott Laboratories Rorer International, and Carrington Laboratories.